Concepts (246)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vaccines | 7 | 2023 | 220 | 2.810 |
Why?
|
| Humans | 58 | 2024 | 17314 | 1.910 |
Why?
|
| Ethnic Groups | 5 | 2021 | 451 | 1.440 |
Why?
|
| Vaccination | 12 | 2022 | 688 | 1.410 |
Why?
|
| Hospitalization | 9 | 2022 | 804 | 1.410 |
Why?
|
| Urinary Tract Infections | 4 | 2022 | 18 | 1.370 |
Why?
|
| Delivery of Health Care, Integrated | 5 | 2022 | 535 | 1.350 |
Why?
|
| Coccidioidomycosis | 2 | 2020 | 5 | 1.240 |
Why?
|
| Male | 32 | 2023 | 9804 | 1.210 |
Why?
|
| Meningococcal Vaccines | 4 | 2019 | 39 | 1.210 |
Why?
|
| Anti-Bacterial Agents | 5 | 2020 | 143 | 1.200 |
Why?
|
| Child | 17 | 2022 | 2403 | 1.190 |
Why?
|
| California | 19 | 2022 | 2311 | 1.190 |
Why?
|
| Female | 34 | 2023 | 12396 | 1.120 |
Why?
|
| Influenza, Human | 3 | 2022 | 282 | 1.120 |
Why?
|
| Lactams | 2 | 2024 | 2 | 1.070 |
Why?
|
| Proline | 2 | 2024 | 6 | 1.060 |
Why?
|
| Nitriles | 2 | 2024 | 8 | 1.060 |
Why?
|
| Leucine | 2 | 2024 | 5 | 1.060 |
Why?
|
| Retrospective Studies | 15 | 2022 | 2415 | 1.030 |
Why?
|
| Adolescent | 17 | 2022 | 3538 | 1.020 |
Why?
|
| Child, Preschool | 13 | 2022 | 1380 | 0.970 |
Why?
|
| Adult | 22 | 2023 | 7500 | 0.960 |
Why?
|
| Enterocolitis, Pseudomembranous | 2 | 2015 | 13 | 0.920 |
Why?
|
| RNA, Messenger | 2 | 2022 | 72 | 0.910 |
Why?
|
| Herpes Zoster Vaccine | 5 | 2016 | 59 | 0.870 |
Why?
|
| Seizures, Febrile | 2 | 2014 | 42 | 0.860 |
Why?
|
| Herpes Zoster | 5 | 2016 | 82 | 0.840 |
Why?
|
| Aged | 19 | 2022 | 6084 | 0.830 |
Why?
|
| Emergency Service, Hospital | 6 | 2022 | 384 | 0.810 |
Why?
|
| United States | 14 | 2023 | 3866 | 0.790 |
Why?
|
| Streptococcal Infections | 3 | 2014 | 22 | 0.790 |
Why?
|
| Infant | 11 | 2022 | 1161 | 0.780 |
Why?
|
| Latent Tuberculosis | 1 | 2022 | 11 | 0.770 |
Why?
|
| Whooping Cough | 4 | 2022 | 65 | 0.760 |
Why?
|
| Young Adult | 13 | 2021 | 2465 | 0.760 |
Why?
|
| Tuberculosis | 1 | 2022 | 24 | 0.760 |
Why?
|
| Orthopedic Procedures | 1 | 2022 | 6 | 0.750 |
Why?
|
| Outpatients | 2 | 2020 | 101 | 0.740 |
Why?
|
| Durable Medical Equipment | 1 | 2021 | 1 | 0.720 |
Why?
|
| Middle Aged | 20 | 2022 | 7836 | 0.710 |
Why?
|
| Cohort Studies | 11 | 2023 | 2514 | 0.690 |
Why?
|
| Minority Groups | 1 | 2021 | 104 | 0.670 |
Why?
|
| Antifungal Agents | 1 | 2020 | 4 | 0.660 |
Why?
|
| Betacoronavirus | 1 | 2020 | 37 | 0.650 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 50 | 0.630 |
Why?
|
| Health Status Disparities | 1 | 2021 | 149 | 0.630 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 57 | 0.630 |
Why?
|
| Drug Prescriptions | 1 | 2020 | 146 | 0.600 |
Why?
|
| Aged, 80 and over | 9 | 2021 | 1925 | 0.600 |
Why?
|
| Coccidioides | 1 | 2018 | 3 | 0.580 |
Why?
|
| Vaccines, Conjugate | 3 | 2019 | 59 | 0.580 |
Why?
|
| Community-Acquired Infections | 1 | 2018 | 20 | 0.570 |
Why?
|
| Influenza Vaccines | 3 | 2022 | 292 | 0.570 |
Why?
|
| Diphtheria-Tetanus-acellular Pertussis Vaccines | 2 | 2022 | 88 | 0.560 |
Why?
|
| Incidence | 8 | 2022 | 1266 | 0.550 |
Why?
|
| Obesity | 2 | 2021 | 814 | 0.550 |
Why?
|
| Meningitis, Meningococcal | 2 | 2017 | 7 | 0.540 |
Why?
|
| Escherichia coli | 2 | 2007 | 8 | 0.520 |
Why?
|
| Bacteremia | 2 | 2013 | 11 | 0.520 |
Why?
|
| Perioperative Period | 1 | 2016 | 5 | 0.500 |
Why?
|
| Cross Infection | 1 | 2015 | 25 | 0.480 |
Why?
|
| Neuralgia, Postherpetic | 1 | 2015 | 12 | 0.470 |
Why?
|
| Herpesvirus 3, Human | 1 | 2015 | 44 | 0.460 |
Why?
|
| Streptococcus | 2 | 2014 | 2 | 0.460 |
Why?
|
| Risk Factors | 8 | 2020 | 3258 | 0.440 |
Why?
|
| Pharyngitis | 2 | 2010 | 10 | 0.430 |
Why?
|
| Bacterial Typing Techniques | 3 | 2010 | 4 | 0.430 |
Why?
|
| Bordetella | 1 | 2013 | 1 | 0.420 |
Why?
|
| Bordetella Infections | 1 | 2013 | 1 | 0.420 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2020 | 16 | 0.420 |
Why?
|
| Ritonavir | 2 | 2024 | 15 | 0.410 |
Why?
|
| Neisseria meningitidis | 1 | 2013 | 10 | 0.410 |
Why?
|
| Livestock | 2 | 2020 | 2 | 0.400 |
Why?
|
| Fever | 3 | 2022 | 54 | 0.360 |
Why?
|
| Streptococcus pyogenes | 1 | 2010 | 6 | 0.350 |
Why?
|
| Carrier State | 1 | 2010 | 8 | 0.350 |
Why?
|
| Case-Control Studies | 3 | 2022 | 1098 | 0.340 |
Why?
|
| Genetic Variation | 1 | 2010 | 77 | 0.330 |
Why?
|
| Time Factors | 3 | 2021 | 1039 | 0.330 |
Why?
|
| Hospitals | 3 | 2022 | 71 | 0.330 |
Why?
|
| Costs and Cost Analysis | 1 | 2020 | 65 | 0.320 |
Why?
|
| Ambulatory Care | 2 | 2022 | 225 | 0.320 |
Why?
|
| Agriculture | 1 | 2018 | 7 | 0.300 |
Why?
|
| Occupational Health | 1 | 2018 | 16 | 0.300 |
Why?
|
| Access to Information | 1 | 2018 | 12 | 0.300 |
Why?
|
| Pandemics | 2 | 2020 | 287 | 0.290 |
Why?
|
| Public Health | 1 | 2018 | 83 | 0.280 |
Why?
|
| Adhesins, Escherichia coli | 1 | 2007 | 1 | 0.280 |
Why?
|
| Fimbriae Proteins | 1 | 2007 | 1 | 0.280 |
Why?
|
| Animals | 4 | 2020 | 280 | 0.270 |
Why?
|
| Sequence Analysis, DNA | 2 | 2012 | 32 | 0.270 |
Why?
|
| Sex Factors | 3 | 2020 | 603 | 0.260 |
Why?
|
| Algorithms | 2 | 2022 | 223 | 0.260 |
Why?
|
| Polymerase Chain Reaction | 3 | 2015 | 52 | 0.260 |
Why?
|
| Age Factors | 3 | 2020 | 878 | 0.250 |
Why?
|
| Body Mass Index | 2 | 2021 | 937 | 0.250 |
Why?
|
| Comorbidity | 2 | 2020 | 560 | 0.250 |
Why?
|
| Headache | 2 | 2022 | 14 | 0.250 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2007 | 363 | 0.250 |
Why?
|
| Myalgia | 2 | 2022 | 10 | 0.250 |
Why?
|
| Escherichia coli Proteins | 1 | 2005 | 1 | 0.250 |
Why?
|
| Clostridium difficile | 2 | 2015 | 22 | 0.230 |
Why?
|
| Brazil | 4 | 2014 | 10 | 0.220 |
Why?
|
| Odds Ratio | 2 | 2018 | 640 | 0.210 |
Why?
|
| Antiviral Agents | 1 | 2024 | 99 | 0.200 |
Why?
|
| Models, Statistical | 2 | 2015 | 170 | 0.200 |
Why?
|
| Neutralization Tests | 1 | 2022 | 3 | 0.200 |
Why?
|
| Antibodies, Neutralizing | 1 | 2022 | 7 | 0.200 |
Why?
|
| Chest Pain | 1 | 2022 | 15 | 0.200 |
Why?
|
| Fatigue | 1 | 2022 | 32 | 0.200 |
Why?
|
| Respiration, Artificial | 1 | 2022 | 36 | 0.190 |
Why?
|
| DNA, Bacterial | 3 | 2013 | 10 | 0.190 |
Why?
|
| Drug Combinations | 1 | 2022 | 43 | 0.190 |
Why?
|
| Diphtheria | 1 | 2022 | 13 | 0.190 |
Why?
|
| Tetanus | 1 | 2022 | 17 | 0.190 |
Why?
|
| Antibodies, Viral | 1 | 2022 | 66 | 0.190 |
Why?
|
| Influenza A virus | 1 | 2022 | 13 | 0.190 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 1 | 2022 | 18 | 0.190 |
Why?
|
| Pneumococcal Vaccines | 1 | 2022 | 68 | 0.190 |
Why?
|
| Organizations | 1 | 2021 | 8 | 0.180 |
Why?
|
| Age Distribution | 3 | 2020 | 239 | 0.180 |
Why?
|
| Aftercare | 1 | 2022 | 47 | 0.180 |
Why?
|
| Electronic Health Records | 3 | 2022 | 704 | 0.180 |
Why?
|
| Electricity | 1 | 2021 | 2 | 0.180 |
Why?
|
| Poverty Areas | 2 | 2010 | 21 | 0.170 |
Why?
|
| Hyperlipidemias | 1 | 2020 | 44 | 0.170 |
Why?
|
| Seasons | 2 | 2022 | 113 | 0.170 |
Why?
|
| Non-ST Elevated Myocardial Infarction | 1 | 2020 | 8 | 0.160 |
Why?
|
| ST Elevation Myocardial Infarction | 1 | 2020 | 7 | 0.160 |
Why?
|
| Patient Discharge | 1 | 2022 | 153 | 0.160 |
Why?
|
| Medicaid | 1 | 2021 | 189 | 0.160 |
Why?
|
| Immunization Schedule | 3 | 2019 | 124 | 0.160 |
Why?
|
| Meningococcal Infections | 1 | 2019 | 17 | 0.160 |
Why?
|
| Population Surveillance | 3 | 2022 | 252 | 0.160 |
Why?
|
| Sex Distribution | 2 | 2020 | 180 | 0.160 |
Why?
|
| Continental Population Groups | 1 | 2021 | 286 | 0.150 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2022 | 381 | 0.150 |
Why?
|
| Risk Assessment | 2 | 2020 | 1076 | 0.150 |
Why?
|
| Immunoassay | 1 | 2018 | 9 | 0.140 |
Why?
|
| Follow-Up Studies | 3 | 2020 | 1151 | 0.140 |
Why?
|
| Hepatitis B Vaccines | 2 | 2014 | 44 | 0.140 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2020 | 302 | 0.140 |
Why?
|
| Risk | 2 | 2015 | 496 | 0.130 |
Why?
|
| Escherichia coli Infections | 2 | 2007 | 6 | 0.130 |
Why?
|
| Asthma | 1 | 2020 | 400 | 0.130 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 390 | 0.130 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 109 | 0.130 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2016 | 13 | 0.130 |
Why?
|
| Diabetes Mellitus | 1 | 2020 | 452 | 0.120 |
Why?
|
| Infection | 1 | 2016 | 17 | 0.120 |
Why?
|
| Policy Making | 1 | 2016 | 13 | 0.120 |
Why?
|
| Proportional Hazards Models | 2 | 2016 | 701 | 0.120 |
Why?
|
| Hypertension | 1 | 2020 | 469 | 0.120 |
Why?
|
| Poisson Distribution | 1 | 2015 | 85 | 0.120 |
Why?
|
| Immunocompetence | 1 | 2015 | 10 | 0.120 |
Why?
|
| Vaccine Potency | 1 | 2015 | 4 | 0.120 |
Why?
|
| Managed Care Programs | 2 | 2014 | 300 | 0.120 |
Why?
|
| Diphtheria-Tetanus-Pertussis Vaccine | 1 | 2015 | 23 | 0.120 |
Why?
|
| Inpatients | 1 | 2015 | 79 | 0.110 |
Why?
|
| Demyelinating Autoimmune Diseases, CNS | 1 | 2014 | 7 | 0.110 |
Why?
|
| Epilepsy | 1 | 2014 | 13 | 0.110 |
Why?
|
| Antigens, Bacterial | 1 | 2014 | 8 | 0.110 |
Why?
|
| Genotype | 2 | 2014 | 223 | 0.110 |
Why?
|
| Kidney Failure, Chronic | 1 | 2015 | 151 | 0.110 |
Why?
|
| Patient Readmission | 1 | 2016 | 161 | 0.110 |
Why?
|
| Antineoplastic Agents | 1 | 2014 | 58 | 0.110 |
Why?
|
| Maternal Age | 1 | 2014 | 74 | 0.110 |
Why?
|
| Regression Analysis | 1 | 2014 | 270 | 0.110 |
Why?
|
| Recurrence | 1 | 2014 | 165 | 0.110 |
Why?
|
| Spleen | 1 | 2013 | 4 | 0.110 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 1 | 2013 | 2 | 0.110 |
Why?
|
| Molecular Typing | 1 | 2013 | 2 | 0.110 |
Why?
|
| Gestational Age | 1 | 2014 | 112 | 0.110 |
Why?
|
| Urban Population | 2 | 2012 | 109 | 0.100 |
Why?
|
| Hepatitis B | 1 | 2014 | 45 | 0.100 |
Why?
|
| Africa South of the Sahara | 1 | 2013 | 2 | 0.100 |
Why?
|
| Models, Immunological | 1 | 2013 | 2 | 0.100 |
Why?
|
| Host-Pathogen Interactions | 1 | 2013 | 4 | 0.100 |
Why?
|
| Mass Vaccination | 1 | 2013 | 22 | 0.100 |
Why?
|
| Minnesota | 1 | 2013 | 51 | 0.100 |
Why?
|
| Papillomavirus Vaccines | 1 | 2014 | 114 | 0.100 |
Why?
|
| Drug Utilization | 1 | 2013 | 121 | 0.100 |
Why?
|
| Feasibility Studies | 1 | 2013 | 108 | 0.100 |
Why?
|
| Multiple Sclerosis | 1 | 2014 | 102 | 0.100 |
Why?
|
| Oregon | 1 | 2013 | 170 | 0.100 |
Why?
|
| HIV Infections | 1 | 2019 | 712 | 0.100 |
Why?
|
| Severity of Illness Index | 1 | 2014 | 437 | 0.100 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 535 | 0.100 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2012 | 1 | 0.100 |
Why?
|
| Interspersed Repetitive Sequences | 1 | 2012 | 1 | 0.100 |
Why?
|
| Gram-Negative Bacteria | 1 | 2012 | 4 | 0.100 |
Why?
|
| Heart Valve Diseases | 1 | 2012 | 17 | 0.100 |
Why?
|
| Reproducibility of Results | 1 | 2013 | 357 | 0.090 |
Why?
|
| Cities | 1 | 2012 | 30 | 0.090 |
Why?
|
| Prevalence | 2 | 2012 | 840 | 0.090 |
Why?
|
| Fluoroquinolones | 1 | 2020 | 5 | 0.080 |
Why?
|
| Chickens | 1 | 2020 | 6 | 0.080 |
Why?
|
| Neoplasms | 1 | 2014 | 446 | 0.080 |
Why?
|
| Community-Based Participatory Research | 1 | 2018 | 46 | 0.070 |
Why?
|
| Primary Health Care | 1 | 2014 | 726 | 0.070 |
Why?
|
| Treatment Outcome | 3 | 2016 | 1160 | 0.070 |
Why?
|
| Sequence Homology | 1 | 2007 | 1 | 0.070 |
Why?
|
| Cluster Analysis | 1 | 2007 | 86 | 0.070 |
Why?
|
| Cross-Sectional Studies | 1 | 2010 | 1280 | 0.070 |
Why?
|
| Infant, Newborn | 2 | 2022 | 805 | 0.060 |
Why?
|
| Cattle | 1 | 2005 | 9 | 0.060 |
Why?
|
| Molecular Sequence Data | 1 | 2005 | 17 | 0.060 |
Why?
|
| African Americans | 2 | 2020 | 439 | 0.060 |
Why?
|
| Cough | 1 | 2022 | 22 | 0.050 |
Why?
|
| Corynebacterium | 1 | 2022 | 3 | 0.050 |
Why?
|
| Temperature | 1 | 2022 | 19 | 0.050 |
Why?
|
| Placenta | 1 | 2022 | 20 | 0.050 |
Why?
|
| Cross-Over Studies | 1 | 2022 | 47 | 0.050 |
Why?
|
| Influenza B virus | 1 | 2022 | 10 | 0.050 |
Why?
|
| Natural Language Processing | 1 | 2022 | 60 | 0.050 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2022 | 56 | 0.050 |
Why?
|
| Oceanic Ancestry Group | 1 | 2020 | 33 | 0.040 |
Why?
|
| Cerebrovascular Disorders | 1 | 2019 | 31 | 0.040 |
Why?
|
| Asian Americans | 1 | 2020 | 163 | 0.040 |
Why?
|
| Vaccines, Inactivated | 1 | 2019 | 72 | 0.040 |
Why?
|
| Vaccines, Combined | 1 | 2019 | 80 | 0.040 |
Why?
|
| Viral Load | 1 | 2019 | 136 | 0.040 |
Why?
|
| Hispanic Americans | 1 | 2020 | 375 | 0.040 |
Why?
|
| European Continental Ancestry Group | 1 | 2020 | 476 | 0.030 |
Why?
|
| Pregnancy | 1 | 2022 | 1463 | 0.030 |
Why?
|
| Bell Palsy | 1 | 2017 | 14 | 0.030 |
Why?
|
| Stroke | 1 | 2019 | 309 | 0.030 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2017 | 93 | 0.030 |
Why?
|
| Immunization, Secondary | 1 | 2016 | 59 | 0.030 |
Why?
|
| Renal Dialysis | 1 | 2015 | 57 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2015 | 80 | 0.030 |
Why?
|
| Immunocompromised Host | 1 | 2014 | 18 | 0.030 |
Why?
|
| Superantigens | 1 | 2014 | 1 | 0.030 |
Why?
|
| Virulence Factors | 1 | 2014 | 1 | 0.030 |
Why?
|
| DNA Primers | 1 | 2014 | 8 | 0.030 |
Why?
|
| Hepatitis B Antibodies | 1 | 2014 | 7 | 0.030 |
Why?
|
| Serologic Tests | 1 | 2014 | 6 | 0.030 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2014 | 15 | 0.030 |
Why?
|
| Hepatitis B virus | 1 | 2014 | 25 | 0.030 |
Why?
|
| Gonorrhea | 1 | 2014 | 19 | 0.030 |
Why?
|
| Chlamydia Infections | 1 | 2014 | 23 | 0.030 |
Why?
|
| Syphilis | 1 | 2014 | 17 | 0.030 |
Why?
|
| Genes, Bacterial | 1 | 2012 | 3 | 0.020 |
Why?
|
| Hospitals, General | 1 | 2012 | 3 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2014 | 277 | 0.020 |
Why?
|
Concepts
(246)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(32)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_
-->